Advanced Prostate Cancer VL

Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming

Details
In an educational session at the 2021 ASCO annual meeting titled Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer, Mark Fleming, MD presented on treatment sequencing in castrate-resistant metastatic cancer (CRPC). In this conversation with Charles Ryan, MD, he speaks to the complex therapeutic landscape and offers guidance in managing treatment se...

Relugolix in the Treatment of Advanced Prostate Cancer- Neeraj Agarwal

Details
Neeraj Agarwal, MD joins Petros Grivas, MD, PhD, sharing his clinical perspective on using relugolix in patients with advanced prostate cancer, and how this new oral treatment option fits into the prostate cancer treatment algorithm. The phase 3 HERO trial looked at patients with advanced prostate cancer, locally advanced prostate cancer, as well as metastatic prostate cancer, and patients were ra...

Transitioning Patients to an Oral GnRH Antagonist and Optimizing Patient Outcomes - Brenda Martone

Details
Advanced Nurse Practitioner, Brenda Martone of Northwestern University Feinberg School of Medicine joins Alicia Morgans, MD, MPH in a discussion on operationalizing the use of the oral GnRH antagonist, relugolix, in clinical practice. They discuss the unique challenges often faced with getting an oral treatment into the patient's hands and talk through the best practices to ensure a successful pro...

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross

Details
In this conversation Alicia Morgans, MD, MPH, and Ashley Ross, MD discuss his considerations of patient selection when using the oral GnRH antagonist, relugolix. Dr. Ross explains his thought process when considering oral ADT therapy for his patients, and outlines three specific scenarios when he leans into recommending its use for his patients and his approach to patient follow-up once oral treat...

Stereotactic Ablative Body Radiotherapy in Patients in Oligometastatic Cancers: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the recently published article in the Lancet Oncology, "Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study." Patients with oligometastatic disease have a more favorable prognosis than those with widespread metastati...

First and Only Oral GnRH Receptor Antagonist Orgovyx for the Treatment of Advanced Prostate Cancer - Charles Ryan & Alicia Morgans

Details
The United States Food and Drug Administration (FDA) approved Orgovyx (relugolix), the first and only oral GnRH receptor antagonist for the treatment of patients with advanced prostate cancer. Alicia Morgans, MD, MPH, and Charles Ryan, MD discuss Orgovyx and what it means to men being treated for advanced prostate cancer who now have an oral ADT treatment option. The FDA approval of Orgovyx is bas...

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer - Karim Fizazi

Details
Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...

PROSPER Trial: Significant Improvement in Metastasis-Free Survival (MFS) and Overall Survival (OS) Demonstrated Nonmetastatic Castration-Resistant Prostate Cancer Patients - Fred Saad

Details
Fred Saad joins Alicia Morgans to discuss the updated data from the PROSPER trial of enzalutamide for nonmetastatic castration-resistant prostate cancer. The updated results show that enzalutamide not only improves metastasis-free-survival, as was indicated by the results published in 2018 but also significantly extends overall survival. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Uro...

HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore

Details
Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. Relugolix is an oral, once a day medication, and the trial had a primary endpoint of non...

Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland

Details
Stephen Freedland joins Alicia Morgans to discuss the Carbohydrate and Prostate Study 2 (CAPS2), a randomized controlled trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer. This study is part of a series of studies looking at the role of low carbohydrate diets in prostate cancer. The study involved taking men with rising PSA after failed s...